{"nctId":"NCT00430248","briefTitle":"Efficacy and Safety of Oral Febuxostat in Participants With Gout","startDateStruct":{"date":"2007-02"},"conditions":["Gout"],"count":2269,"armGroups":[{"label":"Febuxostat 40 mg QD","type":"EXPERIMENTAL","interventionNames":["Drug: Febuxostat"]},{"label":"Febuxostat 80 mg QD","type":"EXPERIMENTAL","interventionNames":["Drug: Febuxostat"]},{"label":"Allopurinol 200 mg or 300 mg QD","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Allopurinol"]}],"interventions":[{"name":"Febuxostat","otherNames":["TMX-67","Tei-6720","Uloric"]},{"name":"Febuxostat","otherNames":["TMX-67","Tei-6720","Uloric"]},{"name":"Allopurinol","otherNames":["Zyloprim"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Has one or more of the American Rheumatism Association criteria for the diagnosis of gout.\n* Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study.\n* Must have a serum urate level greater than or equal to 8.0 milligram per deciliter (mg/dL).\n\nExclusion Criteria:\n\n* Have a severe, unstable, or life threatening medical condition that would likely prevent them from completing this study.\n* Has a known body reaction to febuxostat, allopurinol, naproxen, any other non-steroidal anti-inflammatory drug (NSAID), aspirin, lansoprazole, colchicine, or any components in their formulation.\n* History of xanthinuria.\n* Alcohol consumption greater than 14/week.\n* History of significant concomitant illness.\n* Active liver or peptic ulcer disease.\n* Has rheumatoid arthritis requiring treatment.\n* Has estimated creatinine clearance less than 30 milliliter per minute (mL/min) calculated using the Cockcroft-Gault formula corrected for ideal body weight.\n* Requires therapy with any other urate-lowering drug other than the study drug; long-term use of NSAIDs and COX-2 inhibitors; salicylates; thiazide diuretics; losartan; azathioprine; mercaptopurine; theophylline; intravenous (IV) colchicine; cyclosporine; cyclophosphamide; pyrazinamide; sulfamethoxazole;trimethoprim.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Subjects Whose Serum Urate Level is <6.0 Milligrams Per Deciliter (mg/dL) at the Final Visit.","description":"The percentage of subjects whose serum urate level was \\<6.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate value was collected.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.2","spread":null},{"groupId":"OG001","value":"67.1","spread":null},{"groupId":"OG002","value":"42.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Renal Impairment Subjects Whose Final Visit Serum Urate Level is <6.0 mg/dl","description":"The percentage of subjects with mild-to-moderate renal impairment whose serum urate was \\<6.0 mg/dL at the final visit was summarized. The final visit was the last visit at which a serum urate value was collected.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.7","spread":null},{"groupId":"OG001","value":"71.6","spread":null},{"groupId":"OG002","value":"42.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Month 2 Visit.","description":"Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was \\<6.0 mg/dL at the Month 2 visit was summarized.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.1","spread":null},{"groupId":"OG001","value":"74.1","spread":null},{"groupId":"OG002","value":"43.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Month 4 Visit.","description":"Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was \\<6.0 mg/dL at the Month 4 visit was summarized.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.1","spread":null},{"groupId":"OG001","value":"75.2","spread":null},{"groupId":"OG002","value":"45.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Whose Serum Urate Levels Are <6.0 mg/dL at Month 6 Visit.","description":"Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was \\<6.0 mg/dL at the Month 6 visit was summarized.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.9","spread":null},{"groupId":"OG001","value":"75.3","spread":null},{"groupId":"OG002","value":"46.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Month 2 Visit.","description":"Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was \\<5.0 mg/dL at the Month 2 visit was summarized.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.4","spread":null},{"groupId":"OG001","value":"45.9","spread":null},{"groupId":"OG002","value":"11.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Month 4 Visit.","description":"Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was \\<5.0 mg/dL at the Month 4 visit was summarized.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.0","spread":null},{"groupId":"OG001","value":"51.6","spread":null},{"groupId":"OG002","value":"13.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Month 6 Visit.","description":"Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was \\<5.0 mg/dL at the Month 6 visit was summarized.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.3","spread":null},{"groupId":"OG001","value":"49.7","spread":null},{"groupId":"OG002","value":"14.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Whose Serum Urate Levels Are <5.0 mg/dL at Final Visit.","description":"The percentage of subjects whose serum urate level was \\<5.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate values was collected.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.5","spread":null},{"groupId":"OG001","value":"44.0","spread":null},{"groupId":"OG002","value":"13.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Month 2 Visit","description":"Serum urate values were obtained at the Month 2 visit. The percentage of subjects whose serum urate was \\<4.0 mg/dL at the Month 2 visit was summarized.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":null},{"groupId":"OG001","value":"17.5","spread":null},{"groupId":"OG002","value":"1.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Month 4 Visit","description":"Serum urate values were obtained at the Month 4 visit. The percentage of subjects whose serum urate was \\<4.0 mg/dL at the Month 4 visit was summarized.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"18.6","spread":null},{"groupId":"OG002","value":"1.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Month 6 Visit","description":"Serum urate values were obtained at the Month 6 visit. The percentage of subjects whose serum urate was \\<4.0 mg/dL at the Month 6 visit was summarized.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":null},{"groupId":"OG001","value":"20.3","spread":null},{"groupId":"OG002","value":"1.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Whose Serum Urate Levels Are <4.0 mg/dL at Final Visit","description":"The percentage of subjects whose serum urate level was \\<4.0 mg/dL at the Final Visit was summarized. The Final Visit was the last visit at which a serum urate values was collected.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":null},{"groupId":"OG001","value":"17.5","spread":null},{"groupId":"OG002","value":"1.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change From Baseline in Serum Urate Levels at Month 2 Visit.","description":"Serum urate values were obtained at the Month 2 visit. The percent change in serum urate from baseline to the Month 2 visit was summarized.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.1","spread":"12.8"},{"groupId":"OG001","value":"-44.5","spread":"15.5"},{"groupId":"OG002","value":"-33.8","spread":"13.2"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change From Baseline in Serum Urate Levels at Month 4 Visit","description":"Serum urate values were obtained at the Month 4 visit. The percent change in serum urate from baseline to the Month 4 visit was summarized.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-34.9","spread":"13.1"},{"groupId":"OG001","value":"-45.5","spread":"15.6"},{"groupId":"OG002","value":"-34.5","spread":"12.8"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change From Baseline in Serum Urate Levels at Month 6 Visit.","description":"Serum urate values were obtained at the Month 6 visit. The percent change in serum urate from baseline to the Month 6 visit was summarized.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.6","spread":"13.2"},{"groupId":"OG001","value":"-45.1","spread":"16.0"},{"groupId":"OG002","value":"-34.4","spread":"13.3"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change From Baseline in Serum Urate Levels at Final Visit.","description":"The percent change in serum urate from baseline to the Final visit was summarized. The final visit was the last visit at which a serum urate value was collected.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-33.1","spread":"15.5"},{"groupId":"OG001","value":"-40.6","spread":"19.9"},{"groupId":"OG002","value":"-31.3","spread":"16.2"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":19},"commonTop":["Upper Respiratory Tract Infections","Liver Function Analyses","Diarrhoea (Excluding Infective)","Musculoskeletal and Connective Tissues Signs and Symptoms NEC"]}}}